BIO-TECHNE PRESENTS INITIAL DATA ON SJÖGREN'S SYNDROME MONITORING ASSAY
Bio-Techne Corporation (NASDAQ: TECH) announced that Exosome Diagnostics will present initial data on a non-invasive saliva profiling assay for Sjögren's Syndrome at the 15th International Symposium on Sjögren's Syndrome in Rome, Italy, on September 9, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) announced that Exosome Diagnostics will present initial data on a non-invasive saliva profiling assay for Sjögren's Syndrome at the 15th International Symposium on Sjögren's Syndrome in Rome, Italy, on September 9, 2022. This novel assay utilizes extracellular vesicles to monitor RNA from saliva samples, offering a potential breakthrough in diagnosing and understanding this autoimmune disease. The study demonstrated high accuracy, with AUC values over 0.9. The development of this liquid biopsy tool aims to enhance precision medicine and improve patient care.
Positive
- Development of a non-invasive saliva assay for Sjögren's Syndrome with high accuracy (AUC > 0.9).
- Potential applications for diagnosing other autoimmune diseases.
- Enhancement of precision medicine and patient care through innovative diagnostics.
Negative
- None.
Details
News Market Reaction – TECH
The recorded move for TECH in the trading session of this news was +2.56%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, Sept. 8, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, will present initial data on their novel non-invasive saliva profiling assay for Sjögren's Syndrome diagnosis and monitoring at the 15th International Symposium on Sjögren's Syndrome in Rome, Italy on Friday Sept 9. Exosome Diagnostics' novel Sjögren's Syndrome diagnostic and monitoring tool leverages extracellular vesicles (EVs) to monitor the RNA transcriptome from a small saliva sample.
The data presented highlights a groundbreaking non-invasive monitoring tool to diagnose and understand the pathogenesis of Sjögren's Syndrome from a small saliva sample, with potential applications for other autoimmune diseases. The presentation will be given by Exosome Diagnostics study collaborator, Dr Athena Papas, Professor of Diagnostic Sciences at Tufts School of Dental Medicine (Boston, MA) with the title "Identification of a saliva exosomal-RNA signature for Sjögren's Syndrome". The study included saliva from Sjögren's Syndrome patients as well as from other auto-immune disease patients, including systemic lupus erythematosus and rheumatoid arthritis, as well as necessary controls.
Sjögren's Syndrome is a hard to diagnose auto-immune disease, with impacted patients often on a several year journey before being properly diagnosed, creating a high need for a non-invasive, accurate molecular test. Exosome Diagnostics' saliva EV-based assay has proven to not only being able to stratify these patients, but also profile the molecular pathways that are affected in each patient.
Historically it has been challenging to monitor RNA in saliva but by using the Exosome-based platform, over 12,000 mRNAs were profiled in these samples. The area under the Receiver Operating Characteristic Curve (AUC) values were over 0.9 for identification of Sjögren's Syndrome patients, and identified novel pathways affected in these patients as well as well-known pathways targeting interferon responses and aquaporins.
"We believe this is a very important step forward to enable precision medicine using saliva as the basis for a completely non-invasive liquid biopsy. New tools for diagnosing and monitoring auto-immune disease patients, including Sjögren's Syndrome, are important to improving patient care. Additionally, being able to shed light on what molecular pathways are affected could increase the understanding of the heterogeneity of these diseases, and ultimately lead to more efficient treatment options," said Dr Johan Skog, Chief Scientific Officer at Exosome Diagnostics.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: | David Clair, Vice President, Investor Relations |
612-656-4416 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-presents-initial-data-on-sjogrens-syndrome-monitoring-assay-301619819.html
SOURCE Bio-Techne Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.